AIDS Alert Archives – May 1, 2007
May 1, 2007
View Issues
-
HIV/AIDS advocacy groups say increasing FY08 Ryan White funding will be another challenge
It's been difficult for HIV/AIDS advocacy groups to generate national attention in yet another dismal federal budget year about increasing HIV funding for the newly reauthorized Ryan White Care Act. But there are many signs that the need is at a critical point. -
Adherence Strategies: An effective, inexpensive way to measure adherence
A Connecticut research group wanted to see if they could develop a way to measure HIV medication adherence both cost-effectively and accurately. -
Resistance patterns analyzed in regional study of HIV patterns
A Midwestern clinic showed a high prevalence of primary antiretroviral resistance among HIV patients from 2003 to 2005, suggesting that it's worth the cost to obtain genotypes on new patients, a study suggests. -
FDA Notifications: FDA tentatively approves generic efavirenz
On March 26, 2007, FDA granted tentative approval for a generic drug formulation of efavirenz tablets (600 mg), manufactured by Strides Acrolab Ltd., Bangalore, India, under the expedited review provisions created by FDA for the President's Emergency Plan for AIDS Relief (PEPFAR). -
Posaconazole for Azole-Refractory Candidiasis in Patients with HIV Infection
This paper reports the results of an important multinational trial which evaluated the use of 2 different regimens of posaconazole in the treatment of OPC or EC, which had been refractory to either fluconazole or itraconazole.